Ronnie Luyun, MD
Medical Oncology · Urbana, ILNPI 1346291960
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $569 of the $728 with a category attached, or 78.2%. It is spread thinly across 19 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $259, 9.7 times the $27 reported in 2021. That places this record below the midpoint for medical oncology clinicians in IL, where the typical reported total is $1,059.
Across 33 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$124
- E.r. Squibb & Sons, L.L.C.$97
- Sanofi$66
- Johnson & Johnson$58
- Gilead$50
- Pfizer$38
- plus $295 from 13 others
Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Food & beverage$56978%
- Education$15922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Sanofi | 3 | $66 |
| Johnson & Johnson | 3 | $58 |
| Gilead | 3 | $50 |
| Pfizer | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| AbbVie | 1 | $27 |
| Eisai Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $22 |
| Amgen | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Menarini Silicon Biosystems, Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
How this compares
$728 in reported general payments places this provider in the 40th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 88 | $1,263,729 |
| Abiraterone Acetate | 268 | $838,081 |
| ImbruvicaIbrutinib | 28 | $385,720 |
| XtandiEnzalutamide | 27 | $370,442 |
| CalquenceAcalabrutinib Maleate | 25 | $334,712 |
| LynparzaOlaparib | 21 | $288,357 |
| Lenalidomide | 21 | $287,908 |
| IbrancePalbociclib | 14 | $237,799 |
| TagrissoOsimertinib Mesylate | 12 | $224,346 |
| EliquisApixaban | 78 | $64,372 |
| OxycontinOxycodone Hcl | 20 | $26,416 |
| CreonLipase/Protease/Amylase | 13 | $16,254 |
| Xtampza ErOxycodone Myristate | 15 | $14,765 |
| Risedronate Sodium | 98 | $7,672 |
| Exemestane | 13 | $3,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $58 | $1,263,72988 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20 | $385,72028 claims |
| Astellas Pharma US IncXtandi | $124 | $370,44227 claims |
| PfizerIbrance, Eliquis | $38 | $302,17092 claims |
| AbbVieCreon | $27 | $16,25413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Urbana
- Tanmay SahaiUrbana$3K
- Vamsi VasireddyUrbana$3K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.